Stock gapped down April 2017 from $17 to $10.50 before a further slide to $3.15.
Since that point there has been a steady consolidation period with a slight up trend finally breaking from the ascending triangle with larger than average volume. Retested historic resistence today which held up. I'm looking at this to move into higher highs attempting to cover the gap down over the trading year.
set tight stops due to volatility in both the pharmaceutical industry and tech stocks as of late.
Since that point there has been a steady consolidation period with a slight up trend finally breaking from the ascending triangle with larger than average volume. Retested historic resistence today which held up. I'm looking at this to move into higher highs attempting to cover the gap down over the trading year.
set tight stops due to volatility in both the pharmaceutical industry and tech stocks as of late.
Kommentar:
Trading continues to be range bound after fake-out failed to find legs. still one to watch for potential breaks after such a long period of consolidation